We came across a bullish thesis on Xeris Biopharma Holdings, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research and Rudy Does Research. In this article, we will summarize the bulls’ thesis on XERS. Xeris Biopharma Holdings, Inc.'s share was trading at $7.05 as of December 15th. XERS’s forward P/E was 64.10 according to Yahoo Finance.
[caption id="attachment_570721" align="aligncenter" width="750"]Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.